JNJ Quantitative Stock Analysis

Validea's guru fundamental report rates Johnson & Johnson (JNJ) at 88% using its P/B Growth Investor model, based on Partha Mohanram's strategy for identifying low book-to-market stocks with sustained future growth. This high rating, signifying significant interest, positions JNJ as a large-cap growth stock within the Biotechnology & Drugs sector. While JNJ passed most of the model's fundamental criteria, it notably failed the "Research and Development to Assets" test.

Analysis

Johnson & Johnson (JNJ) receives a strong endorsement from Validea's P/B Growth Investor model, scoring 88% based on the strategy developed by Partha Mohanram. This rating indicates significant interest from a model designed to identify large-cap, low book-to-market stocks with indicators of sustained future growth. The analysis highlights JNJ's fundamental strengths, as the company passed eight out of nine key criteria, including those related to its book-to-market ratio, return on assets (ROA), and cash flow from operations relative to assets. Furthermore, JNJ scored favorably on stability metrics, showing low variance in both ROA and sales, which suggests a high degree of operational consistency. The single point of failure is a critical one for a company in the Biotechnology & Drugs industry: JNJ did not pass the 'Research and Development to Assets' test. This specific weakness contrasts with its otherwise robust financial profile and may signal a potential vulnerability in its long-term innovation pipeline relative to its asset base.

Key Decisions for Investors

• Investors may consider the high 88% score and strength in core fundamentals like ROA and cash flow as a bullish signal, supporting JNJ's profile as a stable growth investment.
• A key due diligence item should be to scrutinize the company's R&D expenditure, as the model's failure on this metric could imply a risk to future growth and competitiveness in the innovation-driven pharmaceutical sector.
• Consider this analysis as one positive data point within a broader research framework, weighing JNJ's current financial stability against the potential long-term implications of its R&D investment strategy.